A neurohealth-focused venture developing a non-invasive diagnostic tool using AI-powered enzyme analysis to detect risk of stroke and Alzheimer’s disease via saliva and serum. Also functions as an incubator supporting health science innovators to accelerate research translation.

Leave a Review

Project Region: Australia

Raise Size (Estimated in USD): 500K to 1M

Fund Stage: Pre-Seed

Investment Type:

Equity

Reasons to Invest:

– First-mover in non-invasive home neurodiagnostics
– Strong medical partnerships & clinical pipeline
– High-impact, scalable solution for global aging crisis

Problem and Solution:

– Early neurodegenerative diseases lack low-cost diagnostics
– Saliva-based AI strip detects key biomarkers like D-serine
– Non-invasive, portable, cost-efficient

Market Opportunity:

– $70B+ diagnostics market
– >5500M with dementia; rising global need for early intervention
– Scalable to public health & aged care

Competitive Advantage:

– Saliva-based at-home solution with AI insight
– Low-cost strips, high diagnostic accuracy
– IP-pending tech with global application

Highlights & Milestones:

– Prototype device completed
– Biomarker validated in multi-region cohorts
– Academic partnerships in AU, MENA & SE Asia

Founder / CEO Language:

English

Verifying Level:

Level 2 - Profile Verified

Translated Level:

Level 1 – Summary Human Translated

We’ll forward your request to the project owner and support your next step.